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ABSTRACT
SYNTHESIS OF HYBRID INOSITOL GLYCAN ANALOGUES
by Sudi Sabet
A 2010 study by Centers for Disease Control and Prevention has projected that 
one of three US adults could have diabetes by the year 2050. More than 90% of the 
diagnosed cases are Type II diabetes, a condition characterized by insulin resistance. In
search of new antidiabetic drugs, a class of natural, phosphorylated, inositol-containing 
pseudosaccharides called inositol glycans (IGs) has been studied for years.  These 
compounds have insulin-mimetic activity in insulin-sensitive cells and can stimulate 
processes such as lipogenesis and glucose transport. Due to the heterogeneity of IGs, it is 
very difficult to isolate them from their natural sources, and the potent synthetic ones are 
complex structures demanding lengthy and laborious chemistry.
It has been observed that a hybrid IG, an inositol-containing disaccharide 
conjugated with a non-carbohydrate fluorophore, exhibits relatively high insulin-mimetic
activity. We propose the generation of a library of similar hybrid IGs (HIGAs), via a 
relatively short synthetic pathway, in which each HIGA is prepared from the attachment 
of the phosphorylated inositol core to a readily available non-carbohydrate piece. The 
ability of each HIGA to activate insulin-sensitive cells will be assayed to identify the 
ones with maximum insulin-like response. The active HIGAs would be further studied in 
future research as potential pharmaceutical agents for treatment of diabetes.
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1CHAPTER 1
INTRODUCTION
1.1 Diabetes Overview
1.1.1 Diabetes
The most recent data, from the diabetes fact sheet of 2011, show that 25.8 million 
Americans (which is 8.3% of the population in the United States) have diabetes.1 In 2010 
alone, 1.9 million new cases were added to this pool. The Diabetes Report Card 2012
indicates that, if the current trend continues, by 2050 one in every three American adults
could have diabetes.2
Diabetes is diagnosed when the concentration of glucose in blood, or glycemia, 
reaches 120 mg/dL or higher. Normally, blood glucose level is controlled by the 
opposing action of two pancreatic hormones, insulin and glucagon. Between meals or 
during physical activity, the glucose level in blood decreases, triggering the pancreas to 
release glucagon. Although many different cell types in the body are responsive to this 
hormone, it mainly stimulates the liver to increase the blood concentration of glucose by
releasing its stored glucose into the blood. On the other hand, after having a meal by
which the glucose level in blood is elevated, the pancreas releases insulin into the 
circulatory system. Again, many tissues respond to this hormone, but mainly insulin 
affects the muscle, liver, and fat cells and instigates the uptake of glucose, which in turn 
lowers the blood glucose concentration.
2The balancing effect of glucagon and insulin maintains the glycemia in the narrow 
range of 4–7 mmol/L (70-100 mg/dL). Various circumstances can cause this system to 
collapse and allow blood glucose to attain much higher levels. This is the main symptom 
of the diabetic condition.
1.1.2 Diabetes Type I
There are two major forms of this disease: Type I or insulin-dependent diabetes 
and Type II or insulin independent diabetes. Type I diabetes is fundamentally an 
autoimmune disease in which the pancreatic β cells that are responsible for production 
and secretion of insulin are attacked by the patient’s own immune system. This 
autoimmune response is induced in susceptible individuals, usually children, by a foreign 
antigen, such as a virus, that immunologically mimics the β cells. Certain alleles of Class 
II major histocompatibility complex (MHC) proteins, which are the normal components 
of the immune system, are prevalent among Type I diabetic patients. When these 
genetically variant proteins are bound to the β cell-resembling antigen, they trigger such a 
strong and prolonged immunological response that eventually, in addition to the foreign 
antigen, the β cells of the patient’s pancreas are eliminated.3 When this loss reaches 80%, 
the patient suffers from acute insulin deficiency which leads to toxic levels of elevated
blood glucose concentration, or hyperglycemia.
From the etiology, it is evident why Type I diabetes is also referred to as insulin-
dependent diabetes. In fact, until the isolation of insulin in 1921 (Figure 1), this disease 
was fatal within days or weeks of the onset.4 However, since then, millions of children 
3and young adults are saved by the administration of exogenous insulin. Although it 
remains a life-changing illness, the majority of patients can maintain a comparatively 
normal life with a robust diet, regular exercise, and routine monitoring of their blood 
glucose level.
(a) (b)
Figure 1. First isolation of insulin. (a) Frederick Banting (right) and Charles Best
purified insulin in summer of 1921 at the University of Toronto. (b) “Insulin: Toronto’s 
Gift to the World” Exhibit went on display in 2011 in Toronto, to celebrate the 90th
birthday of insulin.4
1.1.3 Diabetes Type II
In Type II diabetes the pathology lies on the receiving end of the insulin signal.
Contrary to Type I, at the early stages of the disease, the β cells of the pancreas are 
healthy and able to produce and secrete insulin. In fact, at this stage the patients are 
simultaneously hyperglycemic and hyperinsulinemic (having elevated amounts of insulin 
in the blood).  However, the cells that normally respond to insulin, such as hepatocytes 
(liver cells), adipocytes (fat cells), and myocytes (muscle cells) fail to do so. It seems 
that there is a defect in the insulin signal transduction pathway, a disconnect between 
4receiving the extracellular insulin and generating an intracellular response. In other 
words, insulin-sensitive cells have become insulin resistant.3
1.1.4 Insulin Signal Transduction 
The signaling pathway starts when insulin binds to the alpha subunit of insulin 
receptors (IRs) in the membrane of insulin-sensitive cells. These receptors are 
transmembrane heterotetrameric tyrosine kinases that become activated upon binding 
insulin.5 This results in autophosphorylation of the receptor itself, and tyrosine 
phosphorylation of insulin receptor substrate-1 and substrate-2 (IRS-1 and IRS-2). The 
now activated IRS-1 interacts with the regulatory subunit (p85) of phosphatidylinositol 3-
kinase (PI3K),6 which activates p110, the catalytic subunit of the same kinase.7 PI3K
then phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidyl-
inositol-3,4,5-trisphosphate (PIP3). This molecule then binds to phosphoinositide-
dependent kinase 1 (PDK1) which participates in the activation of Akt, also referred to as
protein kinase B (PKB). Akt/PKB is a critical node in the insulin phosphorylation 
cascade. It phosphorylates a specific site of ATP citrate lyase (ACL), leading to lipid 
biosynthesis, or lipogenesis. It also increases the rate of glycogen synthesis by 
preventing the inactivation of the glycogen synthase (GS). Glycogen synthesis is directly 
up-regulated when glycogen-associated protein phosphatase 1 (PP1), which is activated 
downstream of PI3K, dephosphorylates and hence activates the GS.8 - 9
Perhaps the most well known physiological response associated with insulin is the 
uptake of glucose from the blood and the resulting decrease in blood glucose level. This 
5happens when Akt, either directly or through the activation of other kinases, causes the 
translocation of glucose transporters from the intracellular vesicles to the cell membrane.
There is also a second phosphorylation cascade that leads to the same event and that 
starts when insulin-bound IR phosphorylates APS protein.9 Glucose transporters exist in
several isoforms including glucose transporter 4 (Glut4) that is responsible for insulin-
induced glucose transport. When Glut4 is present on the cell membrane, glucose uptake 
occurs by facilitated diffusion. Figure 2 summarizes these major events of the insulin 
signal transduction pathway.8 - 9
Figure 2. Schematic summary of the major events of the insulin signal transduction
pathway. denotes catalysis, denotes activation, and denotes indirect 
activation.
61.1.5 Diabetes Type II Etiology
A multitude of factors can render cells resistant to insulin. This makes Type II 
diabetes a complex and etiologically heterogeneous disease. The most common risk 
factor is obesity. A recent study lists three ways by which overeating provokes insulin 
resistance: increased inflammation, lipid metabolism alterations, and gastrointestinal 
changes in the microbiota.10
It has been observed that the number of proinflammatory macrophages in adipose 
and hepatic tissues of obese people is substantially higher than in non-obese people.
Genetic loss- and gain-of-function techniques have shown a direct correlation between 
macrophage-mediated inflammation and insulin resistance. For example, in adipose 
tissue, macrophages release a particular cytokine that activates c-Jun N-terminal kinase 
(JNK) and IκB kinase (IKK) that deactivate IRS-1 by serine phosphorylation.10
Unfortunately, anti-inflammatory drug development against diabetes has not been 
successful so far.
Alteration in the metabolism of lipids in obese people is also observed. Such 
changes can result in the lingering of high levels of fatty acids in the blood stream, which
trigger cellular signaling networks that negatively interact with the insulin pathway. For 
example, circulating saturated fatty acids stimulate a member of the toll-like receptor 
(TLR) family, toll-like receptor 4 (TLR4), which is a cell surface, transmembrane protein 
associated with the innate immune system.11 TLR4 in turn activates JNK and IKK, 
linking lipotoxicity and proinflammatory pathways and eventually promoting insulin 
resistance by serine phosphorylation of IRS-1. Secondly, certain byproducts of fat 
7metabolism cause insulin resistance. For instance diacylglycerides (DAGs), produced by 
fatty acids metabolism, activate protein kinase C (PKC), which deactivates IRS-1, again 
by serine phosphorylation. Ceramides, another byproduct of lipid metabolism, prevent 
Akt activity and thus block the insulin signal propagation.10
It is still not very clear if the change in the gastrointestinal microbiome is the 
cause or effect of obesity and insulin resistance. Also, most studies in this area have been 
conducted on mice models, and there are questions on how well they can be translated to 
humans. Nonetheless, these studies show that increased amount of food-sourced energy 
in obesity causes dysbiosis, an imbalance in the otherwise stable intestinal microbiota of 
the individual. Leakage of the bacterial products or bacteria themselves into the 
circulatory system causes proinflammatory responses with adverse effects in insulin 
responsive cells.10
1.1.6 Complications and Treatment 
More than 90% of all cases of diabetes are diabetes Type II. If left untreated,
diabetes causes complications such as cardiovascular disease, which accounts for 50% of 
all fatalities related to this disease. Diabetes is also the main cause of end stage renal 
disease in which patients need dialysis or kidney transplantation. Damage to the nerves,
especially in the toes, feet, and lower limb, causes loss of feeling which consequently 
allows injuries to worsen unnoticed. Eventually, severe infections or gangrenes might 
leave the patient with no other option than amputation. Damage to the retina of the eye
and loss of vision are also common in diabetic patients.
8Currently, there is no cure available. When diagnosed, the patients are advised to 
make major lifestyle changes involving diet and exercise. Usually, after some time,
prescription of antidiabetic drugs are necessary. None of these drugs is perfect and 
scientists are still in search of better ones. In fact, the FDA has recently approved a 
medication by Johnson and Johnson called Invokana® that forces the kidneys to dispose 
of the excess glucose in the urine.12 On the other hand, older medications, like Januvia®
by Merck, are under FDA scrutiny due to new data indicating that they may cause 
cancer.13 So, the quest for better treatment options is by no means over. Although the 
multifactorial nature of Type II diabetes is overwhelming, it does offer multiple 
pharmacological entry points.
1.2 The Second Messenger 
The signaling network that was explained in section 1.1.4 does not have any 
provision to allow one biological event to happen independent of another. As mentioned 
above, glycogen synthesis and glucose transport are prominent physiological responses 
triggered by insulin. Although in most cases these events happen together, it has been 
observed that, in certain tissues and under specific conditions, they are activated
exclusive of each other. For example, when rat heart was treated with insulin, glucose 
transport was observed but not glycogen synthesis. However, in rat diaphragm, insulin 
activated glycogen synthase, but glucose transport stayed dormant.14 In order to explain 
these observations Larner, in 1972, for the first time, hypothesized the presence of a “new 
intermediate”, a second messenger in the insulin signaling pathway.15 Until then, the 
9propagation of insulin stimulation was explained by a phosphorylation network initiated
with the auto-phosphorylation of the insulin receptor tyrosine kinase upon binding to 
insulin. But that model failed to explain the disconnect between insulin-associated 
responses.
The hypothesis gained strength when in 1974 Larner isolated one or more 
compounds from the extracts of insulin treated murine muscle and liver cells that
inhibited protein kinase A (PKA) and activated glycogen synthase phosphatase.14 As
described before, these activities are both associated with insulin. A few years later, 
Jarett and Seal demonstrated that the same compound could activate mitochondrial 
pyruvate dehydrogenase, another insulin-linked event.16 So by 1979, the compound was 
referred to as the “insulin mediator”.17
Identifying the chemical structure of the insulin mediator proved to be an elusive
goal. It was suspected at first that it is a peptide.17 Later, carbohydrates were found in 
the purified compound.18 In 1986, Saltiel made the important discovery that tritiated 
inositol and glucosamine are incorporated in the structure of the mediator and that 
phosphatidyl-inositol phospholipase C was able to release the mediator from the hepatic 
cell membranes.19 Also the polar nature of the compound implied the presence of 
phosphate groups. The exact chemical structure of the insulin mediator was not known
yet, but through ion exchange chromatography, molecular sizing, and phase partitioning 
purification methods, it was determined that it is negatively charged, highly polar, and 
thus water soluble, and weighs between 1000-1500 dalton. All this information 
10
suggested that the mediator is an inositol phosphate glycan (IPG), sometimes known 
more simply as an inositol glycan (IG).20
On the basis of these findings, the biological activity of several already well 
established natural inositol phosphate compounds were auditioned. Neither the chemical 
properties nor the biological effects of the known compounds matched those of the 
insulin mediator. But then a new structure was found, a complex compound that 
anchored proteins in the cell membrane, a glycosylphosphatidylinositol or GPI.
1.3 GPI Anchors
1.3.1 Phosphatidylinositol Phospholipase C
Gangrene, a possible complication of diabetes, is a serious condition caused by a
class of bacteria called clostridia that produce the most diverse array of toxins among all 
bacteria. Ironically these dangerous organisms have also endowed us with a valuable 
biological tool, phospholipase C. Although not categorized as phospholipase C at the 
time, this protein was first discovered in 1941 as the toxin of bacterium Clostridium 
perfringen.21-22 It turned out that phospholipase C is actually a group of enzymes, and,
since some of the members of this group are strong toxins, they have been extensively 
studied. In 1976, scientists succeeded in purifying a type of phospholipase C from 
bacterium Bacillus cereus that specifically acted on phosphatidylinositols and produced 
diacylglycerols and inositolmono -1- and -1-2 cyclicmonophosphates. This enzyme is
referred to as phosphatidylinositol phospholipase C or PI-PLC.21, 23
11
The specificity of PI-PLCs has been exploited in phospholipid composition
studies of membranes.24 It was found that this enzyme released certain proteins such as 
alkaline phosphatase (AP), acetylcholinesterase (AChE), and 5’-nucleotidase that were 
known to reside on the surface of the cell. Prior to this unanticipated observation, 
membrane proteins were believed to be associated with the lipid bilayer in two ways:
through a hydrophobic polypeptide sequence inserted in the membrane or through a 
lipophilic tail that was attached to either the free amine or the thiol function of the 
proteins and secured them into the membrane. PI-PLC experiments suggested a third 
method: anchorage in the lipid bilayer by attachment to a phosphatidylinositol-derived 
structure.23
1.3.2 GPI Anchor Structure
In pursuit of the structural elucidation of the novel membrane protein anchors,
Tse and his coworkers,25 and Ferguson and his collaborators26 made significant 
contributions. Thy-1 glycoprotein, the antigen of rodent thymocytes and neurons, was
the first eukaryotic membrane protein for which a non-protein tail was suggested as the 
membrane anchor. Tse et al., in 1985, demonstrated that the anchor is in fact a 
glycophospholipid structure. Using gas chromatography and mass spectrometry, they 
established that the structure contained of ethanolamine, myo-inositol, stearic acid, 
phosphate, and glycerol.25
Trypanosoma brucei is a protozoan that, like other African trypanosomes, 
confuses the mammalian immune system by expressing the genes encoding variant 
12
surface glycoproteins (VSGs), which form a dense coat covering the cell surface.
Ferguson et al., also in 1985, established that the VSGs are covalently linked to a 
phosphatidylinositol-containing glycolipid that includes a non-N-acetylated glucosamine, 
which is glycosidically attached to a myo-inositol monophosphate. These two important
studies, along with others, established a class of compounds generally referred to as 
glycosylphosphatidylinositols or GPIs.
Since then, an abundance of membrane proteins that use GPI as their anchoring 
system has been discovered. Across the eukaryotic domain, plants, protozoa, fungi, 
yeast, mollusks, insects, and vertebrates benefit from GPI as anchors. Interestingly, none 
has been found in bacteria. In protozoa, free GPIs are also observed on the cell surface.
These structures are not bound to any proteins.
Ferguson et al. discovered the missing pieces of the structural puzzle of T. brucei 
VSG anchor in 1988, making it the first GPI to be completely elucidated.27 Since then,
the structural details of many GPI anchors have been revealed. GPIs are heterogeneous 
in composition, but a conserved core is shared among all. As depicted in Figure 3 the 
core structure of the GPI consists of 6-O-aminoethylphosphoryl-Man(α1-2)-Man(α1-6)-
Man(α1-4)-GlcNH2((α1-6)-myo-inositol-1-O-phospholipid.28 The posttranslational 
addition of the GPI to the nascent protein, the protein destined to mature to a GPI-
anchored membrane protein, is done by a transamidase enzyme in the endoplasmic
reticulum. The point of the addition, also referred to as the ω site, is usually one of the 
smaller amino acids such as Gly, Ala, Ser, Asn, Asp, and Cys and lies upstream of the 
15-30 residue-long, C-terminus signal transamidase sequence of the pro-protein. The 
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transamidase concomitantly adds the GPI to the ω site and cleaves the signal sequence.
The lipid tail of the GPI then gets incorporated into the plasma membrane and anchors 
the mature protein in the outer leaflet.29 - 30
Figure 3. The conserved core structure of GPI anchors.
The aforementioned heterogeneity arises when species- or tissue-specific 
modifications occur at several branching sites of the GPI core. The more common 
changes include the presence of additional mannose residues or phosphate groups and 
branching at the C3 or C4 of the mannose attached to the glucosamine unit (Man I). The
hydrocarbon chain of the GPI phospholipid can vary in length and degrees of 
unsaturation as seen in diacylglycerol, alkylacylglycerol, and ceramide type constituents.
It has also been observed that some GPIs are not sensitive to PI-PLC due to acylation at 
the C2 position of the myo-inositol with extra fatty acids (Figure 4). Instead,
glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), isolated from human 
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serum, hydrolyzes this subfamily of GPIs to phosphatidic acid and an inositolglycan 
piece. In contrast with cleaving product of PI-PLC enzyme, here, the phosphate group 
remains with the lipid moiety. This difference is depicted in Figure 4.23, 31, 32
Figure 4. Cleavage sites of PI-PLC and GPI-PLD on GPI anchor and free GPI. GPIs’ 
structures are simplified to their bare skeleton. 
1.3.3 GPI Anchor Function
The structural complexity of GPI anchors, juxtaposed with the simplicity of lipids 
or peptides that could serve the same purpose, has left the scientific community 
wondering about their evolutionary advantage. Despite considerable efforts to pinpoint 
GPIs’ functions, their only confirmed biological role is anchoring of membrane proteins.
There are some other functionalities attributed to GPI anchors, such as altering the 
structure of their associated protein, involvement in signal transduction, facilitating 
cellular communication, and providing a regulation mode for their associated protein via 
phospholipases, but these remain controversial.27
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Among the possible functions, involvement in signal transduction is the most 
relevant to the subject at hand. One reason that GPIs are associated with signal 
transduction is that the GPI-anchored proteins are localized in lipid rafts, and, since a lot 
of signaling proteins are also gathered in this region, it is hypothesized that GPI anchors 
may also have a role in signal transduction.27 Lipid rafts are microdomains of the cell 
membrane that are packed with sphingolipids, cholesterol, and transmembrane and 
lipidated proteins. They are characterized by insolubility in nonionic detergents such as 
Triton X-100 at 4 ºC. In vitro, lipid rafts are referred to as detergent resistant membranes 
or DRMs. GPI-anchored proteins are also detergent insoluble because of their 
association with lipid rafts. Due to the highly organized structure of the lipid rafts and 
tight packing of their sphingolipids, GPI-anchors are closely packed in this region and are 
suggested to be involved in signal transduction like a lot of other signaling agents in the 
lipid rafts.27, 33 It has also been observed that the product of PI-PLC digestion of the GPIs 
has insulin-like effects.34
1.4 Synthetic IGs
Around the same time that the putative insulin mediators were classified as IPGs,
GPI anchors were discovered and the chemical structure of the VSG anchor was
completely solved. As mentioned earlier, several known inositol phosphate-containing
compounds were surveyed for insulin-like behavior, however the chromatographic and 
electrophoretic properties of these compounds did not match those of the insulin 
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mediator, and none exhibit insulin-like behavior. The novel GPI anchors, being inositol 
phosphate glycans, were appropriately appointed as the next candidate.
To investigate whether GPIs function as precursors to the insulin mediator IPG, 
and to generate large quantities of IPGs for structure-function relationship studies, Misek 
and Saltiel chose to work with the structurally defined Trypanosome brucei VSG1180 
GPI anchor, in 1992.34 In addition to having a defined structure, this GPI was abundantly 
available from the organism. Each T. brucei owned 107 identical copies of the molecule.
It was observed that T. brucei treatment with PI-PLC and Pronase produced an insulin 
mediator-like substance in the medium, which was chromatographically and 
electrophoretically equivalent to the insulin mediators and thus assumed to be an inositol 
phosphate glycan structure. The obtained IPG, which was known to contain myo-inositol
1,2-cylic monophosphate,26 inhibited lipolysis in rat adipocyte and stimulated 
gluconeogenesis in hepatocyte. In order to establish whether the cyclicity of the 
phosphate group on the inositol motif was required for the insulin mimicry, the obtained 
IPG was exposed to acid hydrolysis by treatment with 100 mM HCl for 15 min. The 
product was the more negatively charged acyclic inositol monophosphate glycan that had 
lost its insulinomimetic behavior. Due to these observations, it was suggested that insulin 
triggers a special phospholipase that in turn hydrolyzes the GPI to afford the insulin 
mediator IPG as a 1,2-cyclic monophosphate. In fact, it has been realized that the 
formation of cyclic phosphate on the inositol is ensured by the mechanism through which 
PI-PLC hydrolyzes the phospholipid bond of the GPI.35 The free 2-OH of the inositol 
nucleophilically attacks the 1-phosphate, while the lipid leaves as a fatty acid. For the 
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IPG to act as a mediator, it needs to become deactivated after its signaling function is 
accomplished. The interconversion between the cyclic and acyclic phosphate can serve 
as a switch, turning the IPG mediator “on” or “off”.
By this time it was confidently believed that IPGs are the elusive second
messengers of the insulin pathway.36 It had been observed that, through regulating 
metabolic enzymes such as glycogen synthase, low-Km cAMP phosphodiesterase, 
adenylate cyclase, pyruvate dehydrogenase, phospholipid methyl transferase, protein 
kinase A, and pyruvate dehydrogenase phosphatase, IPGs evoke insulin-related
physiological responses, most importantly lipogenesis. But their structure still was not 
unequivocally resolved. It was known that IPGs contain a free aminohexose that bridged 
a glycan chain and a phosphorylated inositol that was attached though a glycosidic bond.
However, the stereochemistry and substitution was uncertain. Chiro and myo inositols,
various degrees of phosphorylation, and different number and types of sugars in the 
glycan chain have all been detected. The heterogeneity and natural scarcity of the IPGs 
made it hard to obtain pure material, a prerequisite in interpreting the data for biological 
studies. It appeared that chemical synthesis was the only way to have in hand a defined 
structure to be used in uncovering the role of IPGs in insulin signal transduction pathway.
So in 1992, Plourde and d’Alarcao exploited the similarity between the 
structurally defined GPI, used by Misek and Saltiel, and the partially known structure of 
IPGs and designed a short synthetic scheme towards disaccharide 1 and its derivative, 
acyclic phosphate 2 (Figure 5).36 Derivative 2 was not biologically active. However, 40
μM of disaccharide 1 effected the incorporation of 14C-glucose into lipids in intact rat 
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epidydimal adipocytes. At that concentration, 1 was 30-40% as effective as insulin at 
stimulating lipogenesis. This successful outcome shed the spotlight on IPGs and inspired 
many scientists to consider them for research.
Figure 5. Disaccharide 1 is the first biologically active synthetic IPG. Acyclic phosphate 
2, which only differs from 1 in having an acyclic vs. cyclic phosphate group, did not 
show any biological activity.
In an extensive structure-function study in 1998, Müller and collaborators made 
forty-six IPG variants based on the structure of the GPI anchor of the Gce1p membrane 
protein of the yeast Saccharomyces cerevisiae.37 These synthetic IPGs were divided into
four classes, A, B, C, and D, according to their overall insulin-mimetic activity.
Compounds 3 and 4 (Figure 6) were in the most active groups, C and D respectively.
These compounds stimulated lipogenesis, one of the several insulin-related responses 
assayed in this experiment, up to 90% of the maximal insulin response (MIR) at 20 
μΜ. Compound 5 of class B was much less potent with 20% of MIR at 100 mM and 
compound 6 representing class A, was almost inactive. Structure-activity analysis 
revealed that the complete conserved core glycan of the GPI, including the three mannose 
residues, the glucosamine, the mannose side chain in correct glycosidic linkage, and the 
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inositol phosphate moiety were all required for maximal insulin-like activity. The 
phosphate and sulfate anionic substituents had a distinct but unfortunately unpredictable 
influence on the insulin activity of the molecule. By way of example, exchanging the 
terminal sulfate of 3 to phosphate caused considerable decrease in insulin-mimetic
activity of this compound, though interestingly, deviation from the naturally occurring α-
glycosidic linkage between glucosamine and inositol to β-linkage improved the insulin-
like activity of this species.37
Figure 6. Structures 3 and 4 represent the most potent synthetic IPGs ever made with 
lipogenesis activity up to 90% and 80% of MIR. The potency of compound 5 is 20% of 
MIR and compound 6 is almost inactive.
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By 2005, despite great efforts devoted to understanding the molecular basis of 
insulin-mimicry of IPGs, the findings remained incomplete and were conflicting at times.
For example, Alvarez and coworkers38 showed that a natural IPG had to be in the cytosol 
in order to elicit metabolic responses, but Müller and coworkers39 showed that a synthetic 
IPG and a yeast-originated IPG only needed to bind a specific protein on the surface of 
the cell to instigate insulin-like metabolic responses. In order to help explain if one or 
both of these events are necessary to activate the cell, d’Alarcao and coworkers40
prepared a fluorescently labeled pseudodisaccharide, a hybrid between the very first 
biologically active synthetic IG, disaccharide 1, and a commercially available non-
carbohydrate fluorophore, to be able to use optical techniques in tracing the molecule in 
the cellular environment (Figure 7). In order to do so, they replaced the sole primary 
hydroxyl group in 1 with a thiol function so that it could easily react with an 
iodoacetamide derivative of the Lucifer yellow fluorescent tag. The hybrid 7 (Figure 7) 
was added to the growing media of the rat epidydimal adipocytes. After an hour of 
incubation the cells were viewed by fluorescence microscopy and analyzed by flow 
cytometry. They discovered that, although no cellular internalization of the fluorescent 
hybrid occurred, it still stimulated lipogenesis with a maximal activity of 47% of MIR.
The conclusion was that, at least for this hybrid IPG, internalization to insulin-sensitive 
cells is not a prerequisite for insulin-like activity.40
This finding was important, but what was even more intriguing in this experiment
was the fact that, contrary to the scientists’ expectation, the fluorescently conjugated IPG 
had more insulin-like activity than the parent unadulterated carbohydrate.40 They 
21
postulated that the presence of anionic sulfate groups in Lucifer yellow and their position 
relative to inositol are the reasons behind the improved activity. This was a fortunate 
coincidence. Lucifer yellow had been chosen as the fluorescent tag because it would 
become dianionic in physiological conditions. This would prevent nonspecific 
association of the conjugate to the cell surface, which could result in a false positive for 
cell internalization. In addition, it was hypothesized that the locality of these ionic 
substituents on Lucifer yellow may match the IPG’s biologically active sites. A
synthetically significant bonus was that they were added to the molecule via 
commercially available precursors. A logical question followed: are there other 
commercially available non-carbohydrate moieties with opportunistic positioning of the 
ionic groups that would render the simple disaccharide a strong insulin-mimetic
pharmacophore? Answering this question is the goal of the current research.
Figure 7. The structure of fluorescent IPG derived from disaccharide 1.  The sulfate and 
the amine groups are ionic under physiological conditions.
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CHAPTER 2
RESEARCH GOAL AND SYNTHETIC PLAN
2.1 Research Goal
A great body of evidence has suggested that IPGs may act as second messengers
of insulin action. Due to the scarcity and heterogeneity of these compounds, it is difficult
to isolate them from their natural sources in sufficient purity and quantity for biological 
studies. To compensate for these difficulties, scientists have resorted to organic synthesis
to generate structurally defined IPGs in workable quantities.
The most potent IPG synthesized to date is hexasaccharide 3 (Figure 6), which at 
20 μΜ induces insulin-mimetic activity equivalent to 90% of MIR. However,
synthesizing such a complex molecule requires lengthy and arduous carbohydrate 
chemistry. Disaccharide 1 (Figure 5), on the other hand, is much simpler to make, but its
insulin-mimetic activity, at comparable concentrations, is rather modest (less than 30% of 
MIR). Serendipitously, it was also observed that conjugation of 1 to a fluorescent non-
carbohydrate moiety increased the MIR to 47% (cf. 7, Figure 7).
The enhanced biological activity of hybrid 7 was credited to a correct spatial 
distribution of its charged substituents. Therefore, it was hypothesized that there must
exist other commercially available non-carbohydrate moieties with ionizable groups 
positioned as such as to produce even more active hybrids. The current research is 
designed to evaluate this hypothesis. A relatively short synthetic pathway is proposed to 
quickly populate an analogue library of these hybrid inositol glycans to be examined for 
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insulinomimetic biological responses such as glucose uptake, glycogen synthesis, and 
lipogenesis. The structure of the first entry of this library, the first hybrid inositol glycan 
analogue (HIGA), is depicted in Figure 8.
Figure 8. The structure of the first synthesized HIGA with its three parts color-coded: 
phosphorylated inositol core in blue, non-carbohydrate fluorophore in green and a thiol 
linker in red. 
The synthesis of this compound has previously been attempted.41 However, only 
small amounts of the product, enough to be identified by mass spectrometry, were
obtained. The goal of the current work is to improve the reaction schemes and 
conditions, and consequently, the yields, so that sufficient amounts of the HIGAs would 
be synthesized for thorough chemical and biological analysis.
2.2 Synthetic Strategy
One characteristic that active IPGs, such as 1, 3, and 4, have in common is the 
proximity of an amine to the cyclic phosphate on C1 and C2 of the inositol. In the above 
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examples, the amine is part of the glucosamine that is attached to inositol via an α(1-6)
linkage. In order to shorten the synthetic route to HIGAs, this glucosamine was
eliminated. To set the stage for a new protonatable nitrogen close to the cyclic 
phosphate, and for a reactive center to attach the linker, the inositol core was derivatized 
with an azide function at C6. Azide is a stellar functional group for ligation purposes.
There are at least two ligation methods that involve the azide function: Staudinger 
ligation and Huisgen cycloaddition. In both methods, after the ligation has happened the 
azide converts into a protonatable-nitrogen containing system.
The structure of a HIGA (cf. 8 and 9, Figures 8 and 9) consists of three parts, a 
phosphorylated inositol core (blue), a non-carbohydrate fluorophore (green), and a linker 
(red) that attaches the other two pieces together. The initial strategy employed to 
synthesize the first HIGA (cf. 9, Figure 9) involved traceless Staudinger ligation to
connect a cysteine-based linker to the azide derivative of the inositol core. Cysteine was 
desirable since it provided a thiol group as a “hook” for the iodoacetamide non-
carbohydrate fluorophore, and provided an additional amine group, that would neighbor
the cyclic phosphate. However, this strategy had to be abandoned because it still entailed 
too many synthetic steps and involved an intermediate product that failed to form.41
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Figure 9. The structure of the lead HIGA using traceless Staudinger ligation. The three 
parts are: phosphorylated inositol core in blue, non-carbohydrate fluorophore in green, 
and a cysteine-based linker in red.
The second strategy was to employ copper (I) catalyzed regioselective ligation of 
azides and terminal alkynes to fuse a thiol linker to the inositol core. This reaction was 
developed by Barry Sharpless in 200242 and was a new contribution to the family of click 
reactions. It is basically a variant of Huisgen 1,3-dipolar cycloaddition. Contrary to the 
parent reaction, which usually requires elevated temperatures and results in a mixture of 
1,4- and 1,5-disubstituted products, this transformation is simple to run and results in 1,4-
disubstituted 1,2,3-triazole products only. By this reaction, the alkyne side of a thiol 
linker is coupled to the azidoinositol core. The thiol side acts again as a “hook” for the 
iodoacetamide non-carbohydrate moiety, leading to HIGA 8 in 11 fewer steps. Thus the 
second strategy was followed in the previous41 and current work toward the synthesis of 
HIGAs.
The retrosynthetic analysis of HIGA 8 is shown in Schemes 1 and 2. Compound
8 can be obtained by attaching the non-carbohydrate fluorophore, IAEDANS (24), to
thiol 23 by an SN2 reaction. Compound 23 is reached by the exhaustive deprotection of 
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22, converting the benzyl ethers and the benzyl thioether to the corresponding 
unprotected species, the alcohols and the thiol respectively. Compound 22 is the result of 
the phosphorylation of diol 21 with methylpyridinium dichlorophosphate, forming a 
cyclic phosphate that incorporates the vicinal hydroxyl groups at C1 and C2 of the 
inositol. Compound 21 is produced by the “click” chemistry between azide 19b and 
thiol-yne 20. The benzyl-protected thiol-yne 20 is produced by a substitution reaction 
between commercially available α−toluene thiol and propargyl bromide. Compound 19b 
comes about by osmium tetroxide aided syn dihydroxylation of azide 18, which in turn, is 
produced by mesylation and subsequent azide displacement of conduritol 17b. This 
compound has to be purified from an epimeric mixture with 17a (Scheme 2).
Conduritols 17a and 17b are, respectively, referred to as syn and anti conduritol, 
and their synthesis is well established in this laboratory.43 These epimers are the products 
of the ring closing metathesis on a mixture of the 1,6-dienes 16b and 16a, catalyzed by
the first generation Grubbs catalyst.  The dienes are produced from Grignard reaction 
between aldehyde 15 and vinyl bromide. Aldehyde 15 comes from the Swern oxidation 
of alcohol 14, which is the consequence of the addition of a vinyl group to the reducing 
sugar 13 by the Wittig reaction. Compound 13 is made by hydrolysis of the benzylated 
methylglycoside 12. Protection of the non-anomeric hydroxyl groups of 11 by
conversion to benzyl ethers gives fully protected 12.  In turn, 11 is synthesized by Fischer 
glycosidation of commercially available D-xylose, 10.
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Scheme 1. Retrosynthetic analysis of the first HIGA, part 1
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Scheme 2. Retrosynthetic analysis of the first HIGA, part 2
As is evident from this retrosynthetic survey, the non-anomeric hydroxyl groups 
of D-xylose have the stereochemistry of the hydroxyl groups of myo-inositol at positions 
3, 4, and 5, and they stay protected as benzyl ethers until the last step of the synthesis. 
The anomeric position that was protected as a glycoside during the benzylation is
subsequently revealed and utilized as a reactive center to manipulate the molecule toward 
the final product. Additionally, D-xylose is a rather abundant and inexpensive 
compound, which makes it an even more attractive starting material. 
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2.3 Two Strategies Suggested to Selectively Access 17a or 17b
It has been known to this research group that the chromatographic separation of 
syn and anti conduritols, 17a and 17b, is quite inefficient. However, both epimers are 
valuable intermediates in this laboratory. In order to avoid the purification process and 
still have exclusive access to both conduritols, the following strategy was suggested: 
oxidation of the mixture of 17a and 17b to enone 25 and selective reduction of 25 to 
either conduritol (Scheme 3).
Scheme 3. Selective access to 17a or 17b through enone 25
A preliminary literature investigation recommended the use of Dess-Martin 
periodinane for the oxidation step44 and Luche condition,44 the use of DIBAL,45 or bulky 
reducing agents such as LS-Selectride46 (Figure 10) for the reduction step. The Luche 
condition was expected to give the syn conduritol 17a, and LS-Selectride seemed 
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especially promising in producing the other epimer. It was hoped that the steric demand 
of this bulky reducing agent would encourage equatorial hydride attack and improve the 
selectivity toward the axial alcohol, the anti conduritol 17b. That was the first strategy to 
replace the chromatographic separation of syn and anti conduritol and still preserve 
access to both epimers.
Figure 10. Structure of LS-Selectride, lithium trisiamylborohydride, a bulky reducing 
agent.
The second strategy was to employ the Mitsunobu reaction. This reaction is a 
popular method for the inversion of primary and secondary alcohols in organic and 
medicinal chemistry47 and has been used in this laboratory before to interconvert 
chromatographically separated syn and anti conduritol to each other.43 In case the 
equatorial hydride attack of enone 25 did not work as had hoped, the syn conduritol 
obtained from the Luche reduction would be inverted to anti epimer by the Mitsunobu 
reaction (Scheme 4).
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Scheme 4. Selective access to 17b through Mitsunobu inversion of 17a
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CHAPTER 3
RESULTS AND DISCUSSION
3.1 Synthesis of Syn and Anti Conduritols, 17a and 17b
The synthetic scheme and reaction conditions that were followed toward the 
synthesis of the HIGA are summarized in Scheme 5 and Scheme 11. The current
research started with compound 13, which had already been synthesized in large scale
following previously verified methods in our lab.48 However, for the sake of 
completeness and clarity, the three steps leading to 13 from D-xylose are also included in 
Scheme 5. Under glycosidation conditions, D-xylose was refluxed in methanol in the 
presence of acidic dowex for 48 h, affording methyl xyloside 11. Benzylation of 11
resulted in the differentially protected 12. To deprotect the anomeric hydroxyl group, 
12 was hydrolyzed by refluxing under acidic conditions in dioxane for 12 h to afford
reducing sugar 13 in 59% overall yield over the three steps.
Toward the synthesis of the conduritols 17a and 17b, Wittig reagent, methylene-
triphenylphosphorane, was first prepared from a suspension of methyltriphenylphos-
phonium bromide in THF and dropwise addition of butyllithium under strictly anhydrous 
conditions. After the orange-red color of the phosphorus ylide endured for 2 h, the 
solution of 13 in THF was added gradually with stirring. The 5-en-1-ol 14 was obtained 
after a quick filtration of the crude through silica plug. Swern oxidation of 14 gave 5-en-
1-one 15. Grignard reaction of 15 with freshly prepared vinylmagnesium bromide 
resulted in expected (but inseparable) epimers of 1,7-dien-3-ol, 16a and 16b. This 
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mixture was subjected to ring closing metathesis with ruthenium-based first generation
Grubbs’ catalyst which converted 16a and 16b to conduritols 17a and 17b, respectively.
Scheme 5. Synthetic scheme toward first HIGA, part 1, from D-xylose to conduritols 17a
and 17b43
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3.2 Selective Synthesis of 17a and 17b
As mentioned in Section 2.3, since the separation of epimers 17a and 17b using 
silica gel column chromatography required successive purifications and proved to be
extremely inefficient, an alternative route was devised: oxidation of the mixture of the 
two epimers to an enone and stereoselective reduction of the enone to either epimer. To 
this end, using Dess-Martin periodinane, the mixture of 17a and 17b was converted to 
enone 25.44 Reduction under Luche conditions using NaBH4 and CeCl3.7H2O was
attempted in methanol at 25, 0, -20, and -78 ºC and in tetrahydrofuran (THF) at 0 and -78
ºC. Although a mixture of 17a and 17b was observed under all conditions, the selectivity 
toward 17a was greatly improved when the reduction was carried out at the initial 
temperature of -78 ºC in methanol.44 Analysis by NMR (page 72) indicated that, under 
these conditions, the ratio of 17a to 17b was 96 to 4 (Scheme 6).
Scheme 6. Oxidation of 17a and 17b to enone 25 and selective reduction of 25 to 17a
Next, we explored the applicability of DIBAL and LS-Selectride as reducing 
agents toward the selective synthesis of 17b from the enone 25. Two equivalents of 
DIBAL were added to a solution of 25 in dichloromethane at room temperature. TLC 
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indicated the presence of both epimers. The experiment was repeated at -78 ºC, however 
the lower temperature did not improve the selectivity of the reaction toward 17b. The 
reduction was also tried with LS-Selectride, the bulkiest of the reducing agents tried.
Based on analytical TLC, two major unknown products were formed in addition to a 
slight amount of both 17a and 17b. It seemed that the axial attack of the enone by 
reducing agents is not favored enough to allow the stereoselective production of 17b.
This approach was therefore dismissed at this point.
It was decided to produce 17a exclusively by Luche reduction of the enone 25 and 
then epimerize 17a to 17b by the Mitsunobu reaction.43 Traditionally, this reaction is
performed using diethyl azodicarboxylate (DEAD), but due to security measures, it was
difficult to obtain this reagent commercially. Moreover, this exact transformation had
been successfully achieved in d’Alarcao’s group in the past, by a variation of the 
Mitsunobu method.43 Instead of DEAD, equimolar amounts of diisopropyl 
azodicarboxylate (DIAD) was used with equimolar amounts of p-nitrobenzoic acid
(PNB) and triphenylphosphine (PPh3).43
It turned out that the Mitsunobu reaction was extremely water sensitive, and the 
reaction would not simply move forward if there were any trace of water in the solvent or 
the solid reagents. Ultimately, the use of commercial anhydrous ether, drying the solid 
reagents under vacuum in a drying pistol, and increasing the amount of DIAD, PPh3, and 
PNB from one to two molar equivalents of the starting material proved to be effective in 
completely converting 17a to a p-nitrobenzoyl derivative. However, TLC data showed 
the presence of a minor product, that eluted closely with the desired compound. Using 
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preparative TLC, the two products were isolated, and the 1H NMR spectrum of each
(pages 75 and 77) was compared to the references.43 It was confirmed that the two 
products were nitrobenzoate epimers 26a and 26b (7).
Scheme 7. Mitsunobu conversion of 17a to 26a and 26b
The reagents for the reaction are triphenylphosphine (PPh3), p-nitrobenzoic acid (PNB), 
and diisopropyl azodicarboxylate (DIAD).
Nitrobenzoate 26a, the major and the desired product, is produced as the result of 
SN2 reaction between the nucleophilic nitrobenzoate anion (the conjugate base of 
nitrobenzoic acid) and the activated alcohol from 17a. Considering the allylic position of 
the alcohol, the formation of epimer 26b raised a concern over the accessibility of SN2’
mechanistic pathway. Contrary to SN2, in SN2’ both faces of the molecule are open to 
nucleophilic attack, and depending on which face the nucleophile approaches, in addition 
to 26b, the enantiomer of 26a could also form. As illustrated in Scheme 8, that could
compromise the optical purity that has been maintained so far in the synthetic scheme.
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Scheme 8. Possible products of SN2’ reaction
In SN2’ pathway, front side attack of the nucleophile results in 26c. Turning this 
molecule 120º clockwise makes it visually clear that it is the enantiomer of the desired 
product 26a. Back side attack of the nucleophile results in 26d. Again, 120º clockwise 
rotation of this structure makes it visually clear that it is the enantiomer of the structure
26b, the minor product obtained in the Mitsunobu reaction, which could be the result of 
SN1 or a double SN2.
In order to investigate whether the SN2’ pathway is in fact accessible, 26a and, if 
present, its enantiomer, 26c, were separated chromatographically from 26b and its 
enantiomer 26d. The assumed enantiomeric mixture of 26a and 26c were hydrolyzed and 
then derivatized with optically pure (R)-Mosher acid chloride (Scheme 9).49 If the 
material were in fact an enantiomeric mixture, it was expected that the product would be 
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a diasteromeric mixture of Mosher esters 27a and 27b. However, both TLC and NMR
data (page 81) confirmed that only one product, 27a, was obtained from the Mosher ester 
analysis, therefore 26a must have been optically pure. Hydrolysis of 26a gave anti 
conduritol 17b, the NMR data of which matched the literature.43
Scheme 9. Hydrolysis and Mosher ester analysis of 26a and 26c43, 49
Since it is determined that the Mitsunobu reaction does not undermine the optical 
purity of the desired intermediate 17b, Scheme 10 could be adopted as an alternative
“workaround” to gain exclusive access to anti conduritol, 17b, avoiding the inefficient 
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isolation from mixtures with syn conduritol 17a. The overall yield for the “workaround” 
is 45%.
Scheme 10. “Workaround” scheme
3.3 Mesylation and Azide Displacement
Scheme 11 shows the second half of the synthetic scheme. The isolated anti 
conduritol 17b was converted to azide 18, through the intermediacy of its mesylated 
derivative generated by the reaction with methanesulfonic anhydride, and then the azide 
displacement was achieved using sodium azide. Similar to the Mitsunobu inversion, the 
mesylation reaction also resulted in two epimers, 28a (desired product) and 28b (Scheme 
12). These mesylates are reactive species, therefore they cannot be isolated and 
characterized though their presence, and the fact that they are epimers of each other, are
confirmed since their hydrolysis generates syn and anti conduritols, whereas the reaction 
had started with the anti epimer only. After numerous experiments, it was discovered 
that the order of the addition of the reagents affects the ratio of the two products. It is 
important that triethylamine (TEA), which acts as both the catalyst and the base in this 
reaction, be added dropwise after methanesulfonic anhydride is already in the reaction 
mixture. After each drop of TEA, the reaction should be monitored and, once complete,
stopped before the emergence of the undesired epimer 28b, which elutes faster than 28a
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on silica plate.
Scheme 11. Synthetic scheme toward first HIGA, part 2, from 17b to HIGA 8
Scheme 12. Mesylation reaction resulting in two epimers, 28a and 28b
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It was also discovered that the use of 4-dimethylaminopyridine (DMAP) 
improved the efficacy of the reaction and that 28a formed as the major product.50
However, TLC data showed that during the workup some of the product hydrolyzed back 
to the starting alcohol. To avoid this problem, it was planned to proceed directly to the 
azide displacement reaction and skip the aqueous workup. The drawback of this 
approach is the possible formation of two explosive byproducts: mesyl azide and 
diazidomethane. If extra mesyl anhydride remained from the mesylation step, it could 
react with the sodium azide in the next step and form mesyl azide.51 Additionally, if after 
concentrating the mesylation crude some dichloromethane was left behind, it could also 
react with the sodium azide in the next step, producing diazidomethane. The chemical 
shift of the equivalent hydrogens of the diazidomethane is expected to be 4.8 ppm.52
NMR data of the crude product of the mesylation reaction did not have any peak with that 
specific chemical shift, indicating that our reaction conditions were not conducive to the 
formation of that particular byproduct. Nevertheless, extreme caution was taken at this 
step and fortunately there was no trouble. Scheme 13 shows the optimized conditions for 
the two-step transformation from conduritol 17b to azide 18a.
Scheme 13. Use of DMAP in the mesylation step to optimize the reaction conditions
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3.4 Preparation and Separation of the Diols
Osmium tetroxide catalyzed syn dihydroxylation of azide 18 produced diols 19a
and 19b (Scheme 11). The reaction took about a week to complete, and more catalyst, 
osmium tetroxide, and oxidant, N-methylmorpholine N-oxide were added to push the 
reaction to completion. It is important that both the catalyst and the oxidant be added if 
necessary, since it has been observed that addition of the catalyst only could result in the 
formation of a black solid and a dramatically low yield. Separation of 19b, the desired 
diol, from 19a proved to be a challenging endeavor, even by preparative TLC. In order 
to find an optimum chromatography solvent system, different solvent combinations were 
tested (Table 1). Ultimately, it was discovered that addition of one drop of ammonium 
hydroxide per 10 ml of either 1:2 solution of hexane-ether, or neat ether, greatly improves 
the resolution power of these solvent systems. For best results on the preparative TLC,
the diol mixture was once eluted with hexane-ether-NH4OH system and then with ether 
(neat)-NH4OH solution. At this stage the myo-inositol core of the HIGAs is prepared.
Table 1. Solvent systems tried for isolation of 19a and 19b
Solvent system Ratio of solvents Result*
Chloroform : acetonitrile 1 : 1 Not resolved
Chloroform Neat No elution
Chloroform : DCM 1 : 2 No elution
Chloroform : Ether 1 : 2 No elution
DCM Neat No elution
DCM → Ether Neat →Neat Not resolved
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Solvent system Ratio of solvents Result*
DCM : Ether 1 : 2 Not resolved
DCM : Methanol 4 : 1 Eluted w/ solvent front
DCM : Methanol 10 : 0.2 Rf = 0.3, not resolved
Ether Neat Rf = 0.75, resolved poorly
Ether : Hexane : acetonitrile 3 : 3: 1 Rf = 0.5, not resolved
Ether : NH4OH Neat : 1 drop Rf = 0.5,  ΔRf = 0.1
Hexane : Ether 1 : 2.5 Rf = 0.5, poor resolution
Hexane : Ethyl acetate 1 : 2 Rf too high, not resolved
Hexane : Ether : NH4OH 1 : 2 : 1 drop Rf = 0.3, ΔRf = 0.1
Toluene Neat No elution
Dioxane Neat Not resolved
* The reported Rf is for 19b, which elutes faster than 19a on the TLC plate.
3.5 The Click Reaction
Before phosphorylating the inositol core (Scheme 11), the thiol linker is attached 
via copper (I) catalyzed alkyne-azide cycloaddition, the so-called “click reaction”.53 The 
linker was made from commercially available reagents, α-toluene thiol and propargyl 
bromide (Scheme 14).54 Although it was reported previously that the product does not 
stain with p-anisaldehyde,41 in our hands, a white spot was observed. Depending on the 
solvent system, especially if methanol is present, the product may stain light green.
NMR analysis revealed that the green color of the stain is indicative of the co-elution of 
an impurity. A solution of 6 to 1 ether-hexane proved to be a good solvent system for 
isolating the pure triazole 21 (Scheme 11). Uncharacteristic of the click chemistry, the 
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reaction between 19b and 20 produced many side products, and the isolated yield was 
never more than 50%. 
Scheme 14. Preparation of thiol linker 2054
3.6 Phosphorylation of the Model Diol 31 and Triazole 21
The phosphorylation reaction that converts diol 21 to phosphate 22 needs freshly 
prepared N-methylpyridinium dichlorophosphate which is provided from anhydrous 
pyridine and commercially available methyl dichlorophosphate (MeOPOCl2) (Scheme 
15).55 It has been shown by others that it is prudent to evaluate the efficacy of this 
reagent in creating a cyclic phosphate on a model compound, before letting it react with 
the precious synthetic intermediate.56 In order to do so, the model diol 31 (Scheme 16)
was prepared from myo-inositol following a previously reported synthesis.57 First, two of 
the three vicinal cis diols of myo-inositol were protected as a cyclohexylidene. Although
the literature reported 93% yield for this step, in our hands, it resulted in multiple side 
products that adversely affected the yield (2%). The next step was the benzylation of the 
remaining hydroxyl groups. During the workup of this step, the presence of bromine was 
detected by the yellow color of the ethyl acetate solution. Therefore, 1% aqueous sodium 
thiosulfate was used to reduce the bromine before the workup was completed. Acidic 
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hydrolysis of the cyclohexylidene proceeded smoothly, and an adequately pure diol was
obtained after the first crystallization.
Scheme 15. Preparation of the phosphorylating reagent, N-methylpyridinium 
dichlorophosphate
Scheme 16. Synthesis of the model diol 31
During the preparation of the phosphorylating reagent (Scheme 15), it was 
expected that white turbidity would develop within a half hour of mixing the reactants.58
If this was not observed, the reaction was discarded and the quality of the reactants were 
examined. The phosphorylation reaction was then undertaken by addition of the
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phosphorylating reagent to the solution of the model diol 31 in anhydrous pyridine
(Scheme 17). Since pyridine hindered TLC-monitoring, the reaction was instead 
monitored by mass spectrometry. When the mass of the starting material disappeared 
from the spectrum, the reaction was considered complete. Significantly, it was noticed
that the successful formation of the cyclic phosphate, as confirmed by 31P NMR, and 
hence the potency of the phosphorylating reagent could be judged by a mass signature:
the presence of m/z = 682.25 and 620.24 and the absence of m/z = 621.22. The 
calculated exact mass of the phosphorylated model diol is 602.21.
Scheme 17. Synthesis of the model phosphate 32
Two different workup procedures were attempted for the phosphorylation
reaction. In the first one,56 established by this research group, the reaction was
simultaneously quenched and neutralized by the addition of saturated sodium 
bicarbonate. Then the solvents were co-evaporated with heptane. The residue was
dissolved in water, carefully adjusted to pH=1, and extracted with ethyl acetate. This 
step is time consuming, but it guarantees the protonation of the phosphate group, and thus
promotes the solubility of 32 in organic solvent. The other workup method is much 
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simpler and faster.58 It calls for 25 times dilution of the reaction mixture with 
dichloromethane and 3 times wash with brine. However, after trying both methods and 
realizing that silica gel chromatography of 32 is not possible because of extremely low 
yields, the first approach was favored since it resulted in a cleaner product. It should be 
noted though, that as indicated by 31P NMR, the cyclic phosphate group survived both 
workup procedures without hydrolyzing to an acyclic one.
After it was determined how to confirm the potency of the phosphorylating 
reagent and to monitor the reaction using mass spectrometry, the phosphorylation 
reaction was carried out on the triazole 21. The phosphorylating reagent was first used 
on the model diol, and, after the mass signature was observed, it was added to the 
pyridine solution of 21. Mass spectrometry showed the presence of the cyclic phosphate 
22 (Scheme 11) and consumption of all the starting material. 
3.7 Deprotection of the Model Phosphate 32
The first time deprotection was tried on compound 22, using dissolving-metal
reduction, the reaction failed. No trace of the starting material or the product was 
detected even by mass spectrometry. Hydrogenolysis has been employed before in this 
laboratory to deprotect the benzyl groups of a disaccharide.56 It was observed that the 
presence of the amine group on the benzylated disaccharide interfered with accessing the 
deprotected compound after hydrogenolysis, so the deprotection was achieved by
dissolving-metal reduction using liquid ammonia and sodium. Nonetheless, it was 
planned to try hydrogenolysis on 22 hoping that the triazole would not behave like an
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amine. However, literature research led us to another example in which the triazole 
moiety deactivated the palladium catalyst and prevented the hydrogenolysis of the benzyl 
groups.59 Therefore, it was decided to stay with the dissolving-metal reduction as the 
deprotection method but to optimize it on the model compound 32 prior to deprotecting 
the synthetic intermediate.
In the literature procedure that was followed, solid ammonium chloride was added 
to quench the reaction, and, when the blue color of the solvated electrons disappeared, 
methanol was poured in. However, in our hands, the reduction was successful when the 
workup was changed as follows: after the addition of ammonium chloride, the reaction 
was let to stir overnight, allowing liquid ammonia to evaporate without adding methanol. 
The solids that were left behind were dissolved in methanol the next day and 
concentrated. The residue was desalted using Sephadex G10. 31P NMR and mass 
spectrometry confirmed the presence of salt free phosphorylated inositol 33 (Scheme 18).
Scheme 18. Deprotection of the model phosphate 32
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CHAPTER 4
CONCLUSION AND FUTURE DIRECTIONS
The challenges of each step of the synthesis, from the mixture of conduritols to
the global deprotection, were successfully overcome. The inefficient isolation of the anti 
conduritol from its mixture with the syn epimer was addressed by designing a 
“workaround” scheme in which the mixture of syn and anti conduritols was oxidized to 
an enone. The syn conduritol was then exclusively obtained by Luche reduction of the 
enone, and the anti conduritol was afforded by Mitsunobu inversion of the syn epimer. 
Enantiomeric analysis of the Mitsunobu intermediates suggested strongly that the route to
SN2’ is inaccessible and the optical purity of the product is maintained by the 
“workaround” scheme. The conditions of the mesylation reaction were optimized so as 
to obtain the desired product in considerable preponderance. A drop of ammonium 
hydroxide was all that was needed to separate the diols by preparative TLC, and leaving 
methanol out of the solvent system was found to be the key to a pure click product. An 
unexpected but consistently observed mass predicted the efficacy of the phosphorylating 
reagent in creating cyclic phosphates, and reevaluating the established workup procedure 
made the deprotection with dissolving-metal reduction a success.  
Toward the synthesis of HIGA, the synthetic phosphate will be deprotected 
following the newly found method, and, at the last step, the exposed thiol function of the 
linker will be reacted with the non-carbohydrate fluorophore, IAEDAN, to produce the 
first HIGA. It might be prudent to determine if the triazole function present in the linker
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survives the deprotection method, maybe by designing a model triazole. The reaction of 
the thiol group with IAEDAN is expected to progress smoothly according to the 
established protocols. In the future, the synthetic scheme could be repeated to prepare 
other HIGAs containing different non-carbohydrate moieties. The HIGAs will be 
assayed for insulinomimetic biological activity in insulin-sensitive cells by comparing the 
amount of glucose uptake in the presence and the absence of HIGAs.
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CHAPTER 5
EXPERIMENTAL PROCEDURES
Reagents and solvents purchased from commercial sources (Fisher Scientific, 
Sigma Aldrich, or Life Technologies) were used without further purification with the 
following exceptions: methylene chloride was distilled from calcium hydride. Pyridine 
and triethylamine were distilled from barium oxide. Tetrahydrofuran (THF) and 
diethylether were distilled from sodium benzophenone ketyl. Reactions that required 
anhydrous conditions were performed under argon or nitrogen atmosphere with prior 
drying of hygroscopic solids by azeotropic co-evaporation with toluene or ethyl acetate.
The progress of the reactions was monitored by thin layer chromatography (TLC) 
on SiliaPlate glass backed silica gel plates (0.25 mm thickness) with a 254-nm 
fluorescent indicator. Visualization was achieved either by ultraviolet illumination or by 
staining the plates with ethanolic solution of p-anisaldehyde (2.5% p-anisaldehyde, 3.5% 
sulfuric acid, and 1% acetic acid) and then baking on a hot plate. Organic extracts 
collected during workups were dried over MgSO4 and concentrated in vacuo on a rotary 
evaporator. Purifications were carried out by flash chromatography on SiliaFlash silica 
gel (40-63 µm ), preparative TLC, or gel filtration using Sephadex G-10. Nuclear 
magnetic resonance (NMR) data were gathered using Inova-400 MHz NMR spectrometer 
and were reported in parts per million (δ) relative to internal standard tetramethylsilane 
(TMS) for 1H, 13C, or external standard H3PO4 (85% in D2O) for 31P. Mass spectrometry 
data were obtained on Agilent 6520 Quadrupole Time-of-Flight LC/MS mass
spectrometer using electrospray as the ionization method (ESI-MS).
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(2R,3R,4S)-2,3,4-Tris(benzyloxy)hex-5-en-1-ol (14).48
This reaction was performed under extremely anhydrous conditions. All glassware and 
needles were flame-fried. THF was freshly distilled from a sodium benzophenone ketyl
solution. Methyltriphenylphosphonium bromide was dried in a drying pistol in the 
presence of phosphorus pentoxide and heated in hot water bath for 3 days. Xylose 13
was azeotroped with toluene three times. A three-neck flask was setup to accommodate a 
dropping funnel, an argon inlet, and a rubber septum to be used for injecting the reagents.
To the suspension of dried methyltriphenylphosphonium bromide (13.13 g, 36.74 mmol) 
in anhydrous THF, in the three-neck flask, was added butyl lithium (21.77 mL of 1.6 M 
hexane solution) dropwise, at 0 ºC. The color of the reaction mixture was exptected to 
turn orange-red upon formation of phosphonium ylide. More equivalents of butyl 
lithium were prepared to be added in case the reaction wouldn’t go to completion. After 
the red color was maintained for 2 h, the solution of 13 (5.3 g) in THF (42 ml) was added 
to the phosphonium ylide solution using the dropping funnel. The reaction was stirred 
over night at room temperature and refulxed for 2 h after TLC ( hexanes-EtOAc, 7:3)
indicated that the reaction was complete. The reaction was diluted with NH4Cl (60 ml, 1 
M) and water (100 mL) and extracted with ether twice. Combined organic layers were 
THF, 45 oC
PPh3=CH2
13 14
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BnO
BnO
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BnO
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washed with brine, dried over MgSO4, and concentrated. The crude was quickly filtered 
through a 4” long silica plug using 15% and then 30% ethyl acetate in hexane to afford 
2.8 g of pure 14 in 54% yield. 1H NMR (CDCl3): δ = 7.37 – 7.24 (m, 15H), 5.88 (ddd, J
= 17.7, 10.5, 7.4 Hz, 1H), 5.33 – 5.28 (m, 2H), 4.74 (s, 2H), 4.63(d, J = 12.0 Hz, 1H),
4.61 (s, 2H), 4.37 (d, J = 12.0 Hz, 1H), 4.10 (m, 1H), 3.73 – 3.48 (m, 4H), 1.97 (br s, 1 
H).
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(2S,3R,4S)-2,3,4-Tris(benzyloxy)hex-5-enal (15).48
All glassware and needles were flame-dried and kept under argon till used. To a dry 
flask was transferred anhydrous methylene chloride (30 mL) and cooled to -78 ºC.
Oxalyl chloride (2.13 mL, 0.0249 mol, 98% pure) and DMSO (3.53 mL, 0.0498 mol) was 
syringed in, dropwise. Evolution of gases was observed and the reaction mixture turned 
cream in color. Stirring continued for another 15 min. Alcohol 14 (5.2 g, 0.0124 mol) 
dissolved in 30 mL of dry methylene chloride was added dropwise into the reaction 
mixture, at -78 ºC, and stirred for 30 min, after which time triethylamine (13.8 mL) was 
added dropwise. The cloudy reaction mixture was stirred for another 5 min and then was
let to warm to room temperature. After TLC (hexanes-EtOAc, 7:3) indicated the 
completion of the reaction, it was diluted with water and extracted with methylene 
chloride. The organic layer was washed with 1 M NH4Cl, water, then brine, and dried 
over MgSO4. Since TLC indicated a pure product the crude was kept frozen in benzene 
to be used in the next reaction without any purification. 1H NMR spectrum was not 
obtained.
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(3S,4R,5R,6S)-4,5,6-Tris(benzyloxy)octa-1,7-dien-3-ol (16a) and (3R,4R,5R,6S)-4,5,6-
tris(benzyloxy)octa-1,7-dien-3-ol (16b).48
To a flame-dried three-neck flask was attached a mechanical stirrer, a condenser, and a 
rubber septum. Finely cut magnesium ribbons (3.2 g, 0.130 mol) were dropped into the
flask and freshly distilled THF (65 mL) was syringed in. The flask was lowered in an ice 
bath, and after 5 min, vinyl bromide (15 mL) was quickly poured in. To initiate the 
reaction, the flask was removed from the ice bath, but was returned to it as the
progression of the reaction generated heat and gas. When no change was observed after 
about an hour the reaction was let to run at room temperature until a deep dark green 
color was observed and magnesium ribbon cuts were consumed. To the prepared 2M 
vinylmagnesium bromide, cooled to -78 ºC, was added methylene chloride (300 mL) and 
then the solution of aldehyde 15 (5.4 g) in methylene chloride (15 mL). The reaction was 
complete, after 4 h, as indicated by TLC (hexanes-EtOAc, 8:2), quenched with methanol, 
and brought to room temperature. It was then washed with water, 1 M NH4Cl, again 
water, and brine, dried over MgSO4 and concentrated. The crude was purified by flash 
chromatography over silica gel, eluting with (hexane-EtOAc, 85:15) to afford 3.03 g of
CH2Cl2:THF; 5:1
BrMg , -78 oC
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the inseparable mixture of 16a and 16b as a yellowish oil (52%). 1H NMR of the mixture 
was identical to what was previously reported.48
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(1S,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-ol (17a) and 
(1R,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-ol (17b).43
To a stirred solution of 16a and 16b (3.03 g, 6.82 mmol) in methylene chloride was 
added first generation Grubbs’ catalyst (0.590 g, 7.18 mmol), at room temperature and
under argon atmosphere, to produce a deep dark purple color. The reaction was complete
in 24 h as indicated by TLC (hexane-EtOAc, 7:3) and concentrated. After four iterations
of flash chromatography (silica gel, hexanes-ether, 1:1) 17a was obtained as a white flaky 
solid (1.3 g) and 17b was afforded as a dark, brown oil (470 mg), with total yield of 68%.
For 17a, 1H NMR (CDCl3): δ = 7.25 - 7.36 (m, 15H), 5.70 (m, 2H), 5.03 (d, J = 11.3 Hz, 
1H), 4.92 - 4.25 (m, 5H), 4.32 - 4.25 (m, 2H), 3.79 (dd, J = 7.4, 10.2 Hz, 1H), 3.53 (dd, J
= 8.0, 10.1 Hz, 1H), 2.22 (d, J = 3.9 Hz, 1H).
For 17b 1H NMR (CDCl3): δ = 7.35 - 7.25 (m, 15H), 5.88 (d, J = 1.9 Hz, 2H), 4.94 - 4.66
(m, 6H), 4.29 (m, 1H), 4.10 (d, J = 7.4 Hz, 1H), 4.50 (dd, J = 7.2, 9.7 Hz, 1H), 3.56 (dd, J
= 4.1, 9.7 Hz, 1H), 2.71 (d, J = 2.5 Hz, 1H).
CH2Cl2, 45 min
17a 17b
(Cy3P)2RuCl2(CHPh)
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(4S,5R,6S)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-one (25).44
To 17a and 17b (42.5 mg, 0.10 mmol) dissolved in CH2Cl2 (0.6 mL) were added 
NaHCO3 (42 mg, 0.50 mmol) and Dess-Martin periodinane (86.5 mg, 0.20 mmol) at 
room temperature. After 40 min. sat. aq. Na2S2O3 was added and the reaction stirred 
vigorously until it turned clear. The reaction was partitioned between CH2Cl2 and sat. aq. 
NaHCO3, the layers were separated, and the aqueous layer was extracted once with 20 
mL CH2Cl2. The combined organic layers were washed with brine, dried over MgSO4
and concentrated to give clear oil. Purification over silica gel (hexanes-EtOAc, 8:2)
afforded a light yellowish viscous oil (39.2 mg, 94%). 1H NMR (CDCl3): δ = 7.46 - 7.30
(m, 15H), 6.82 (dd, J = 2.0, 10.2 Hz, 1H), 6.05 (dd, J = 2.4, 10.4 Hz, 1H), 5.10 (d, J =
11.2 Hz, 1H), 4.98 (d, J = 11.2 Hz, 1H), 4.79 (m, 4H), 4.37 (dd, J = 2.4, 8.0 Hz, 1H), 
4.02 (m, 2H). 
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(1S,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-ol (17a).44
Enone 25 (80 mg, 0193 mmol) was taken up in methanol (3.21 ml) at room temperature
and stirred until it was completely dissolved. The reaction flask was submerged into an 
acetone/dry ice bath for 10 minutes after which time CeCl3.7H2O (93.5 mg, 0.25 mmol) 
and sodium borohydride (18.1 mg, 0.48 mmol) were added. To help start the reaction, 
the flask was removed from the -78 ºC bath. TLC (ethyl acetate:hexane, 4:6) indicated 
the completion of the reaction after 1.5 h. The reaction was terminated and worked up as 
follows: Separated between ethyl acetate and water, the aqueous layer was extracted with 
ethyl acetate, and combined organic layers were dried over MgSO4. After purification 
(silica gel, hexane-ether, 1:1) 38.6 mg of syn conduritol 17a was obtained (48%). The 1H
NMR spectrum of the product matched what was previously reported.43
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(1R,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-yl 4-nitrobenzoate (26a) and 
(1S,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-yl 4-nitrobenzoate (26b).43
This reaction is extremely water sensitive. Triphenylphosphane (PPh3) and p-
nitrobenzoic acid (PNB) were dried in drying pistol for 24 h. The starting material 17a (9
mg, 0.0220 mmol), was azeotroped with ethyl acetate three times. PPh3 (12 mg, 0.0440 
mmol) and PNB (7.2 mg, 0.044 mmol) were added to the starting material, and the 
content was azeotroped one last time. Commercially obtained anhydrous ether (0.38 mL, 
0.058 M) was added at room temperature. After most of the material had dissolved and 
no more change was observed, 2 equivalents of diisopropyl azodicarboxylate (DIAD)
(8.72 μL, 0.0440 mmol) was syringed into the mixture. The reaction occurred violently 
and instantaneously with disappearance of all of the starting material. The reaction 
mixture was concentrated under reduced pressure and the major and the minor products
were isolated by preparative TLC (hexanes-ether, 8:2) with 72% yield for the major 
product. For 26a: 1H NMR (CDCl3): δ = 8.28 (d, J = 8.5 Hz, 2H), 8.18 (d, J = 8.5, 2H), 
7.36 - 7.23 (m, 15H), 6.04 - 5.87 (m, 3H), 4.99 - 4.67 (m, 6H), 4.16 - 4.04 (m, 2H), 3.73 
PPh3, PNB, DIAD
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O2N
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O2N
+
26b Minor product
Ether
26a Major product
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(dd, J = 3.0, 9.9 Hz, 1H).
For 26b: 1H NMR (CDCl3): δ =8.24 (d, J = 8.8 Hz, 2H), 8.02 (d, J = 8.8 Hz, 2H), 7.36 -
7.10 (m, 15H), 5.83 (m, 2H), 5.64 (d, J = 10.5 Hz, 1H), 4.98–4.67 (m, 6H), 4.30 (dd, J =
2.8, 4.7 Hz, 1H), 3.93 - 3.85 (m, 2H).
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(1R,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-ol (17b).43
To a stirred solution of 26a (4 mg, 0.0071 mmol) in THF (0.1 mL, 0.07M), was added aq.
1 M LiOH (0.1 mL). The reaction mixture was stirred overnight at room temperature.
After that time TLC (EtOAc-hexanes, 4:6) indicated the completion of the reaction. The 
solvent was evaporated and 2.3 mg of anti conduritol 17b was isolated by preparative 
TLC (EtOAc-hexanes, 4:6). (77%) The 1H NMR data of this product matched what was 
previously reported (page 63 of this document).
THF-H2O
LiOH
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(S)-(1R,4S,5R,6R)-4,5,6-Tris(benzyloxy)cyclohex-2-en-1-yl 3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate (27a).49
To a solution of 17b (2.3 mg, 0.0055 mmol, obtained from Mitsunobu conversion of 
17a), Et3N (2.3 μL, 0.017 mmol, 3 eq), and DMAP (~ 1 mg, small crystal) in CHCl3 was
added 37 μL of 0.178M solution of (R)-Mosher acid chloride (0.0066 mmol) in benzene.
Since after 2 days the reaction did not go to completion 8 more equivalents of the Mosher 
acid chloride solution and 3 more equivalents of Et3N was added to the reaction mixture.
After TLC (EtOAc-hexanes, 2:8) indicated the consumption of all starting material, the 
solvents were evaporated under reduced pressure and the residue was let to stir with 3
drops of water over night. The reaction mixture was diluted with CHCl3 and washed with 
saturated sodium bicarbonate (2x) and 0.1M HCl (2x). The organic layer was 
concentrated to produce 27a. 1H NMR (CDCl3): δ = 7.52 (d, J = 8.4 Hz, 2H), 7.27 - 7.13
(m, 18H), 5.88 (dd, J = 2.4, 9.8 Hz, 1H), 5.83 (dd, J = 4.0, 4.0 Hz, 1H), 5.68 (m, 1H), 
4.83 (d, J = 10.8 Hz, 1H), 4.73 (d, J = 11.2 Hz, 1H), 4.66 (d, J = 9.2 Hz, 1H) 4.64 (d, 9.6 
OBn
BnO
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BnO
17b
Cl
O
OCH3F3C
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(R)-Mosher's acid chloride
DMAP, Et3N, CHCl3
27a
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Hz, 1H), 4.57 (d, J = 11.2 Hz, 1H), 4.49 (d, J = 11.6 Hz, 1H), 4.05 (d, J = 8.0 Hz, 1H), 
3.87 (dd, J = 8.0, 10.8 Hz, 1H), 3.62 (dd, J = 4, 10.8 Hz, 1H), 3.46 (s, 3H).
19F NMR (CDCl3): δ = -71.0, -71.8.
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((((1R,2R,3S,6S)-6-Azidocyclohex-4-ene-1,2,3-triyl)tris(oxy))tris(methylene))
tribenzen (18).50
To triply toluene-azeotroped conduritol 17b (32.8 mg, .0788 mmol) was added mesyl 
anhydride (27.5 mg, 0.1577 mmol) and DMAP (38.5 mg, 0.3152 mmol). The reaction 
flask was kept under argon and distilled DCM (657 mL) was syringed in. The progress 
of the reaction was monitored by TLC (EtOAc-hexanes, 2:3) and when no more change 
was observed, Et3N was added, one drop at a time. The effect of each drop was TLC-
monitored. After the completion of the reaction, sodium azide (53.8 mg, 0.8274 mmol) 
and DMF (400 mL) was added (Caution: mesyl azide, which is an explosive can form at 
this stage). The reaction was stirred behind a shield for 2 h after which time TLC 
(EtOAc-hexanes, 1:4) indicated the completion of the reaction. NaOH (10% ) was added 
to the reaction which was stirred for another 15 min, and then extracted with DCM. The 
organic layer was washed with water, HCl, water again and then brine. The aqueous 
layer was extracted with DCM and the combined organic layers were dried over MgSO4
and concentrated in vacuo to afford dark brown oil. The crude residue was purified by 
preparative TLC (EtOAc-hexanes, 1:4) to give 14.2 mg of 18 (41% yield). 1H NMR 
(CDCl3): δ = 7.35 - 7.25 (m, 15H), 5.70 (d, J = 10.4 Hz, 1H), 5.47 (d, J = 10 Hz, 1H), 
1. Ms2O, DMAP, Et3N
2. NaN3, DMF
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4.94 - 4.66 (m, 6H), 4.11 (m, 2H), 3.70 (dd, J = 8.0, 10.4 Hz, 1H), 3.55 (dd, J = 8.4, 10 
Hz, 1H).
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(1R,2R,3S,4R,5S,6S)-3-Azido-4,5,6-tris(benzyloxy)cyclohexane-1,2-diol (19a).
(1S,2S,3S,4R,5S,6S)-3-Azido-4,5,6-tris(benzyloxy)cyclohexane-1,2-diol (19b).43
To a solution of 18 (3.9 mg, 0.0088 mmol) in water: acetone (1:9, 440 μL) N-methyl 
morpholine N-oxide (1.5 mg, 0.0132 mmol) was added followed by osmium tetraoxide 
(22.4 mL of aqueous solution of osmium tetroxide (10 mg/mL)). The reaction mixture 
was stirred under argon for about a week until TLC (hexanes-ether, 1:1) indicated the 
completion of the reaction. Diethyl ether (4 mL) was added to the reaction mixture, and 
the organic layer was washed with 10% aqueous sodium thiosulfate (1.5 mL) followed by 
water (1.5 mL) and dried over MgSO4. The solvent was evaporated to give crude residue 
as yellow oil. 1H NMR data shows the ratio of 19a:19b to be 1:2.6. This mixture was 
purified by two consecutive preparative TLCs (hexanes-ether, 1:2 plus 1 drop of NH4OH
per 6 ml of organic solvents) to (neat ether plus 1 drop of NH4OH per 6 ml of ether) with 
isolated yield of 31% for 19b. 1H NMR for 19b (CDCl3): δ = 7.35-7.25 (m, 15H), 5.77 
(d, J = 2.32 Hz), 4.94 - 4.66 (m, 6H), 4.18 (m, 1H), 4.02 (d, J = 7.24 Hz), 3.90 (dd, J =
7.44, 7.44 Hz), 3.46 (dd, J= 4.12, 4.12 Hz), 2.59 (bs, 1H).
OBn
BnO
N3
BnO OsO4, NMO
Acetone: H2O, 9:1
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benzyl(prop-2-yn-1-yl)sulfane (20).54
α-Toluene thiol (2 g, 16.1 mmol) was dissolved in degassed methanol (0.5 M, 32.2 mL) 
at 0 oC, and solid KOH (1.08 g, 19.2 mmol) was added to the reaction mixture. After 5 
min., propargyl bromide, 80% in toluene (2.58 mL) was added, and the reaction mixture 
was warmed to room temperature. After 16 h, TLC (EtOAc-hexanes, 1:9) indicated 
minor amount of starting material remaining. The reaction was stopped by removal of 
the methanol under vacuum, and the residue was diluted with water (12 mL), extracted 
with ethyl acetate (2 x 25 mL), dried over MgSO4 and concentrated in vacuo. The crude 
yellow oil was purified by flash chromatography (hexanes → hexanes-EtOAc, 9:1) to 
give 20 (1.9 g, 75% yield) as yellow oil. 1H NMR (CDCl3): δ = 7.38 - 7.27 (m, 5H), 3.88 
(s, 2H), 3.08 (d, J = 2.8 Hz, 2H), 2.31 (t, J = 2.6 Hz, 1H).
SH
+
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SKOH
degassed MeOH
20α-toluene thiol Propargyl bromide
96
S 20
97
S 20
98
(1S,2S,3S,4S,5R,6S)-3,4,5-Tris(benzyloxy)-6-(4-((benzylthio)methyl)-1H-1,2,3-
triazol-1-yl)cyclohexane-1,2-diol (21).53
A solution of propargyl sulfide 20 (3.61 mg, .022 mmol) in THF (50 μL) was added to 
19b (5.9 mg, 0.0124 mmol) at room temperature and the reaction mixture was let to stir.
Copper sulfate pentahydrate (0.3 mg, 0.00124 mmol, 50 μL of 6 mg/ml stock solution) 
followed by sodium ascorbate (0.5 mg, 0.00248 mmol) were added to the reaction 
mixture. TLC (neat ether) indicated complete disappearance of starting material in less 
than 10 min. Water (0.3 mL) was then added to the reaction mixture and the aqueous
layer was extracted with ethyl acetate (2 x 0.5 mL). The organic layer was washed with 
water (0.5 mL) and brine (0.5 mL), dried over MgSO4 and concentrated in vacuo. The 
crude residue was purified by preparative TLC to afford 21 (4 mg, 51% yield) as a white 
solid. 1H NMR (CDCl3): δ = 7.57 (s, 1H), 7.34 - 7.15 (m, 20H), 6.90 (dd, J = 3.6, 6.8 Hz, 
2H), 4.94 (d, J = 11.2 Hz, 1H), 4.90 (d, J = 11.2 Hz, 1H), 4.84 (d, J = 3.2 Hz, 1H), 4.78 
(d, J = 11.2 Hz, 1H), 4.59 (d, J = 10.4 Hz, 1H), 4.40 (d, J = 10.8 Hz, 1H), 4.29 (s, 1H), 
4.21 (d, J = 10.8 Hz, 1H), 3.94 (d, J = 9.6 Hz, 2H), 3.68 - 3.59 (m, 5H), 2.1(bs, 2H).
HRMS (ESI): m/z [C37H39N3O5S]+ cald 638.2688, obsd 638.2684.
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1,2-O-cyclohexylidene-D/L-myo-inositol (29).57
In a two-necked flask, myo-Inositol (4.707 g, 26.13 mmol) and cyclohexanone (40 mL, 
385.9 mmol) were added in a 1:1 mixture of DMF (50 mL) and benzene (50 mL). The 
reaction mixture was heated to reflux in a Dean-Stark apparatus and p-toluenesulfonic
acid monohydrate (p-TsOH.H2O) (0.202 g, 1.06 mmol) in DMF (5 mL) was added to the 
reaction flask in 1.25 mL aliquots at 2 h intervals. The mixture was cloudy at first but 
after 10 h changed to a clear pale yellow. The reaction was heated for another 24h. The 
solvents were then removed by vacuum distillation to leave a viscous orange liquid that 
was taken up in hot EtOH (100 mL) and left to cool slowly to crystallize. The solid was 
filtered and re-crystallized from EtOH to give 29 as white needle-like crystals (300 mg, 
2%). 13C NMR (DMSO): δ109.2, 79.5, 76.7, 75.7, 74.9, 73.5, 73.0, 72.6, 70.6, 38.3, 
35.6, 25.3, 24.3, 24.0
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Cyclohexanone, p-TsOH
DMF/PhH (1:1), reflux, 24 h
myo-inositol 29
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(±)-3,4,5,6-Tetra-O-benzyl-1,2-O-cyclohexylidene-myo-inositol (30).57
Tetraol 29 (300 mg, 1.15 mmol) was transferred to a 2-necked 50 mL round bottom flask 
and azeotroped with toluene over night. Anhydrous THF (2.8 mL) was added to the flask 
and the mixture was cooled to 0 oC. To this was added NaH (276 mg, 6.90 mmol, 60% 
dispersion in mineral oil) and, after stirring for 30 min tetrabutylammonium iodide
(TBAI) (212 mg, 0.58 mmol) was added followed by slow addition of benzyl bromide 
(0.84 mL, 7.04 mmol) and the reaction mixture was heated to reflux for over night. The 
reaction was then quenched first with MeOH and then H2O; the mixture was washed with 
EtOAc and the combined organic layers washed with brine and dried over MgSO4. The 
crude product was purified by column chromatography, twice, using hexanes to remove 
excess benzyl bromide and EtOAc-petroleum ether (1:9) to isolate 30 as an oily product 
(540 mg, 84%). 1H NMR (CDCl3): δ = 7.41-7.25 (m, 20H), 4.94 - 4.74 (m, 8H), 4.29 (t,
J = 4 Hz, 1H), 4.1 (t, J = 5.2 Hz, 1H), 3.95 (t, J = 8.4 Hz, 1H), 3.82 (t, J = 9.6 Hz, 1H),
3.7 (dd, J = 4.0, 8.4 Hz, 1H), 3.42 (dd, J = 8.4, 9.6 Hz, 1H), 1.9 - 1.4 (m, 10H).
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(±)-1,4,5,6-Tetra-O-benzyl-myo-inositol (D/L-31).57
Acetal 30 (400 mg, 0.644 mmol) was dissolved in 80% aq acetic acid (4.03 mL) and 
heated to a gentle reflux for 2 h. The solvent was evaporated under reduced pressure and 
the crude product crystallized at 0 oC from a mixture of toluene/PE (1:3) to give D,L-31 as
a white solid that was re-crystallized from EtOAc/PE (1:4) (278 mg, 80%). 1H NMR 
(CDCl3): δ = 7.34 -7.26 (m, 20H), 4.94 - 4.72 (m, 8H), 4.21 (dd, J = 2.4, 2.7 Hz, 1H),
3.97 (dd, J = 9.6, 9.3 Hz, 1H), 3.84 (dd, J = 9.6, 9.3 Hz, 1H), 3.51 - 3.45 (m, 3H), 2.49 (s, 
1H), 2.41 (d, J = 4.5 Hz, 1H).
HOAc (80% aq)
reflux, 2 h
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(±)-1,4,5,6-Tetra-O-benzyl-myo-inositol 1,2-cyclic phosphate (32).56, 58
All glassware and syringes were dried in hot oven over night. MeOPOCl2 (500 μL) was 
added to dry pyridine (5 mL) very slowly. The reaction was stirred at room temperature 
for 30 min to make a white turbid mixture. This mixture (1.3 ml, 50 eq) was added to a 
stirred solution of 31 (14 mg, 0.0259 mmol) in dry pyridine (0.43 mL) under argon and 
stirring was continued at room temperature for an hour. The completion of the reaction 
was determined by mass spectrometry confirming the disappearance of starting material 
at which time reaction was quenched by addition of saturated NaHCO3 (10 mL) and co-
evaporation with heptane (10 mL). The resulting solid was dissolved in water (0.75 mL) 
and adjusted to pH=1 by dropwise addition of 2 M HCl. The solution was extracted with 
EtOAc (5 x 0.5 mL) and the combined organic extracts were dried over MgSO4 and 
concentrated in vacuo, to afford a crude white solid (12 mg, 78%). 1H NMR (CDCl3): δ
= 7.35 - 7.11 (m, 20H), 4.81 - 4.43 (m, 10H), 4.17 (dd, J = 8, 9 Hz, 1H), 3.75 (dd, J = 6, 
6.4 Hz, 1H), 3.635 (s, 1H), 3.35 (dd, J = 7.2, 8.6 Hz, 1H), 1.62 (bs, 1H). 31P NMR 
(CDCl3): δ = 19.7 ) 
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D-myo-inositol -1,2 cyclic phosphate (33).56
Anhydrous gaseous ammonia was liquefied at -78 ºC in a three-neck flask equipped with 
acetone-dry ice filled condenser. When 7 mL of liquid ammonia was collected, the 
ammonia line was closed and the flow of argon was resumed. Elemental Na (96.6 mg), 
kept under mineral oil, was rinsed with hexane and dropped into the flask, which caused 
the liquid ammonia to immediately turn in very dark royal blue. After the color persisted 
for 15 min, the crude 26 (12.5 mg, 0.0210 mmol) dissolved in THF (4.6 mL) was 
syringed in slowly. No color change was observed. After 15 min NH4Cl (390 mg) was
added to quench the reaction. In few minutes, the blue color disappeared and formation 
of salts was observed. The reaction was let to stir over night, and allowed to reach room 
temperature. The white solid that was left behind after the liquid ammonia evaporated,
was dissolved in methanol, concentrated and dissolved in water (1 ml) to be loaded on
Sephadex G10 (12 g) column for desaltation. The presence of salts was indicated by the 
precipitation of white silver chloride upon addition of 1 drop of silver nitrate solution to 1 
drop of the fractions. The white precipitate of silver chloride indicated the presence of 
salt. 1H NMR shows the absence of benzyl groups (The presence of impurities 
complicated the 1H NMR interpretation. Since this was a model compound, further 
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purification was not pursued). 31P NMR (D2O) δ : 17.7. HRMS (ESI): m/z [C6H12O8P]+
cald 243.0270, obsd 242.9180 ; m/z [C6H14O9P]+ cald 261.0375, obsd 260.9256; m/z
[C6H11NaO8P]+ cald 265.0089, obsd 264.8451.
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